Related Experiment Video
Updated: Nov 26, 2025
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
The Coronavirus Pandemic: A Pitfall or a Fast Track for Validating Cell Therapy Products?
Maroun Khoury1,2, Laertis Ikonomou3, Massimo Dominici4
1Laboratory of Nano-Regenerative Medicine, Faculty of Medicine, Universidad de los Andes, Santiago, Chile.
Abstract:
The global COVID-19 pandemic has prompted urgent need for potential therapies for severe respiratory consequences resulting from coronavirus infection. New therapeutic agents that will attenuate ongoing inflammation and at the same time promote regeneration of injured lung epithelial cells are urgently needed. Cell-based therapies, primarily involving mesenchymal stromal cells (MSCs) and their derivatives, are currently investigated worldwide for SARS-CoV-2-induced lung diseases. A significant number of academic centers and companies globally have already initiated such trials. However, at a time of unprecedented need, it is also foreseen that families and caregivers will seek all available options, including access to cell-based and other investigational products, even before proven safety and efficacy as well as regulatory approval. This should not be an excuse for opportunists to sell or advertise unproven therapies of any kind. "Compassionate use" should be conducted in the context of a clinical investigation framed by strict ethical and regulatory permissions, with the goal of obtaining mechanistic information wherever possible.
Insights
Mesenchymal stromal cells (MSCs) show promise for treating COVID-19 lung injury by reducing inflammation and aiding lung repair. Ethical clinical investigations are crucial for compassionate use of these novel therapies.
Area of Science:
- Regenerative Medicine
- Pulmonology
- Infectious Diseases
Background:
- The COVID-19 pandemic necessitates novel therapies for severe respiratory complications.
- Lung epithelial injury and inflammation are key pathological features of SARS-CoV-2 infection.
- Cell-based therapies, particularly mesenchymal stromal cells (MSCs), are under investigation for treating these lung conditions.
Purpose of the Study:
- To explore the potential of MSCs and their derivatives as therapeutic agents for COVID-19-related lung diseases.
- To address the urgent need for treatments that can simultaneously reduce lung inflammation and promote epithelial regeneration.
- To emphasize the importance of ethical and regulatory frameworks for compassionate use of investigational cell therapies.
Main Methods:
- Investigational studies worldwide are exploring the efficacy of MSC-based therapies for SARS-CoV-2-induced lung injury.
- Clinical trials are being initiated by academic centers and biotechnology companies.
- Focus on obtaining mechanistic insights through ethically approved compassionate use protocols.
Main Results:
- MSC-based therapies are being actively investigated globally for their potential to treat COVID-19 lung disease.
- A significant number of clinical trials are underway, indicating strong research interest.
- The abstract highlights the need for rigorous investigation rather than unproven commercialization.
Conclusions:
- Mesenchymal stromal cells (MSCs) represent a promising avenue for therapeutic intervention in COVID-19 lung injury.
- Strict ethical and regulatory oversight is paramount for compassionate use of investigational cell therapies.
- Future research should prioritize well-designed clinical investigations to establish safety and efficacy.
